Current location: Home > PRODUCTS > Real Time PCR Series Products

PRODUCTS

NTRK Gene Fusions Mutation kit 

(Real-Time PCR assay)

CE-IVD


INTRODUCTION OF NTRK GENE

The neurotrophin receptor tyrosine kinase (NTRK) family includes three proteins, TRKA, TRKB, and TRKC, encoded by the NTRK1, NTRK2, and NTRK3 genes, these proteins are normally expressed in neural tissues. Activation of TRK structures by NTRK gene fusions is considered as a pan-cancer oncogenic factor.

NTRK gene fusions are found in a variety of adult and pediatric solid tumors. In extremely rare tumor types such as infantile fibrosarcoma and secretory carcinoma, the frequency of NTRK fusion is more than 90%; in common cancers, the fusion frequency is between 0.1% and 2% [1].



NTRK gene fusion profiles in adult and pediatric tumors[1]



NTRK AND TARGETED THERAPY 

Although the frequency of NTRK fusions is low in common cancers, the efficacy of NTRK inhibitors is very obvious in patients with fusions. The FDA approved larotrectinib and entrectinib in 2019 and 2020 for the treatment of patients with advanced solid tumors without alternative therapy or progression,who carry NTRK fusion-positive. This is the second and third pan-entity FDA-approved tumor-targeted therapy. In clinical trials, the overall response rate (ORR) of larotrectinib and entrectinib reached 75% and 57%, this was achieved after 82% and 63% of the enrolled population had progressed on more than one systemic therapy [2].

Based on the above approval, the National Comprehensive Cancer Network has included NTRK inhibitors in several clinical diagnosis and treatment guidelines. The Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of non-small cell lung cancer (NSCLC) have also included NTRK inhibitors in the first-line treatment of stage IV NTRK-fusion NSCLC [3]. The detection of NTRK fusions is also recommended in guidelines such as CSCO colorectal cancer.



DETECTED GENES 

Reaction Tube

Splicing Genes

 and Exons

NTRK Exon Reaction Tube

Splicing Genes

 and Exon

NTRK Exon

LMNA E2

NTRK1 E10

MPRIP E14

NTRK1 E11

LMNA E10

NTRK1 E10

MPRIP E18

NTRK1 E11

LMNA E11

NTRK1 E10

MPRIP E21

NTRK1 E11

SQSTM1 E5

NTRK1 E9

NTRK-3

LMNA E6

NTRK1 E1

NTRK-1

TPM3 E8

NTRK1 E9

TPM3 E8

NTRK1 E11

NACC2 E4

NTRK2 E12

SSBP1 E12

NTRK1 E11

SQSTM1 E5

NTRK2 E13

STRN E3

NTRK2 E16

VCL E16

NTRK2 E13

QKI E6

NTRK2 E16

TFG E5

NTRK1 E9

NTRK-4

EVT6 E4

NTRK3 E14

TFG E6

NTRK1 E9

EVT6 E5

NTRK3 E15

NFASC E21

NTRK1 E9

EVT6 E4

NTRK3 E15

CD74 E8

NTRK1 E9

EVT6 E5

NTRK3 E14

NTRK-2

TPR E21

NTRK1 E9

EML4 E2

NTRK3 E15

TPR E10

NTRK1 E9

TFG E6

NTRK3 E1

IRF2BP2 E1

NTRK1 E9

BCAN E12

NTRK1 E10

BCAN E13

NTRK1 E9

LMNA E5

NTRK1 E9


PRODUCT INFORMATION

Product Name

Technology

Pack Size

Instruments Validated

Sample Type

NTRK Gene Fusions 

Mutation kit 

Real-Time PCR assay

20 Tests/Kit

Stratagene Mx3000P™,

ABI7500 etc

Tumor tissue,

Pleural and ascites


DETECTION SIGNIFICANCE  

Before systemic treatment in patients with advanced or metastatic solid tumors, NTRK gene fusion detection is performed for molecular typing to help guide treatments.



FEATURES & ADVANTAGES

1.Accuracy and Reliability:Use pre-load  PCR tube to effectively avoid cross-contamination.

2.High Sensitivity:Sensitivity can reach as low as 100 copies in RNA.

3.Comprehensive Coverage:Covers the 32 most common variants of the NTRK. 

4.Great versatility:Validated on the most common qPCR machines with stable results.


 DETECTION PROCESS                             

1.Nucleic Acid Extraction

2.Set up qPCR

3.Amplification

4.Data Analysis


[1] J Mol Diagn. 2019 Jul;21(4):553-571.

[2] FDA official website data 

[3] CSCO NSCLC Diagnosis and Treatment Guidelines 2021

[4] CSCO Colorectal Cancer Diagnosis and Treatment Guidelines 2021